In this study, the prevalence of DNMT3A mutation is 7.9 and 7.7% in MDS according to the FAB and 2016 WHO classification, respectively (Table 1), similar to most of the previous reports (7.8 to 10%) [12, 40–42] but higher than that of Thol et al. (2.6%) [13]. This evidence concerns the gene DNMT3A and myelodysplastic syndrome.